BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI
6727 therapy in terms of drug-related adverse events when combined with a platinum therapy
(cisplatin or carboplatin).
Secondary objectives are the collection of overall safety and antitumour efficacy data and
the determination of the pharmacokinetic profile of BI 6727 combination treatment with
cisplatin and carboplatin.